Brit J Heamatol: Incidence and prognosis of heparin-induced thrombocytin-induced thrombocytin in patients with solid malignancies

Heparin-induced thrombocytin (HIT) is an adverse reaction of the body to immunomediated reactions to heparin products, characterized by or not accompanied by thrombosisRecently, a study published in the Journal of The Journal of Blood Systems, published in the journal British Journal of Haematology, which aims to identify the incidence, morbidity, mortality, and economic burden of HIT in hospitalizations associated with solid malignanciesresearchers analyzed the National Inpatient Sample Database (NIS), the largest public database of inpatients in the United States between January 2012 and September 2015The main outcomes of the study were the incidence of HIT, and the secondary outcomes included venous thrombosis (acute deep vein thrombosis and pulmonary embolism), arterial thrombosis (thrombosis stroke, myocardial infarction, and other arterial thrombosis), HIT-related mortality, hospital time, total hospitalization costs, and disposition7437049 patients were hospitalized and diagnosed as solid malignancies during the study periodIn this population, about 0.08% (n-6225) had HIT in the secondary diagnosis of hospitalized patientsCompared to patients with meta-malignant tumors without HIT, the standardized incidence of total thrombosis events in patients with HIT was higher (24.7% vs6.8%, P 0.001)The standard mortality rate for patients with solid malignant tumors with HIT was 4.8%, while the standard mortality rate in patients with physical malignant tumors without HIT was 3.4% (OR 1.53; 95% CI was 1.25-1.89; P 0.001)shows that HIT is a rare disease in patients with solid malignant tumors, but increases morbidity and mortality in such patients